NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ARMP

Armata Pharmaceuticals Inc

Jul 02 • 04:00PM ET

1.94

Dollar change +0.05
Percentage change 2.65	%

Healthcare • Biotechnology • USA • AMEX

Peers: SRPT SAGE OCUL GALT TGTX PTCT BCRX TXMD CRBP MNOV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	70.20%	Shs Outstand	36.19M	Perf Week	-2.51%
Market Cap	70.22M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.79M	Perf Month	-0.51%
Enterprise Value	193.19M	PEG	-	EPS next Q	-0.39	Inst Own	2.05%	Short Float	1.24%	Perf Quarter	32.88%
Income	-0.43M	P/S	14.94	EPS this Y	-117.98%	Inst Trans	-46.04%	Short Ratio	0.53	Perf Half Y	-3.96%
Sales	4.70M	P/B	-	EPS next Y	-	ROA	-0.41%	Short Interest	0.13M	Perf YTD	4.86%
Book/sh	-1.49	P/C	6.01	EPS next 5Y	-	ROE	-	52W High	3.42 -43.20%	Perf Year	-25.95%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	18.34% 26.80%	ROIC	-	52W Low	0.90 116.01%	Perf 3Y	-48.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.96% -	Gross Margin	70.80%	Volatility	5.51% 7.51%	Perf 5Y	-52.22%
Dividend TTM	-	EV/Sales	41.10	EPS Y/Y TTM	99.47%	Oper. Margin	-859.76%	ATR (14)	0.17	Perf 10Y	-99.85%
Dividend Ex-Date	-	Quick Ratio	0.12	Sales Y/Y TTM	0.00%	Profit Margin	-9.07%	RSI (14)	52.89	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.12	EPS Q/Q	73.94%	SMA20	0.17%	Beta	0.99	Target Price	9.00
Payout	-	Debt/Eq	-	Sales Q/Q	-49.17%	SMA50	11.39%	Rel Volume	0.01	Prev Close	1.89
Employees	60	LT Debt/Eq	-	Earnings	May 14 AMC	SMA200	-1.82%	Avg Volume	254.77K	Price	1.94
IPO	May 20, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	47.37% -64.42%	Trades		Volume	2,881	Change	2.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-19-19	Initiated	Ladenburg Thalmann	Buy	$9

May-21-25 09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks) -6.67%
May-19-25 07:00AM	Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia (PR Newswire) +75.56%
May-14-25 05:45PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update (PR Newswire)
09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:55PM	Loading…
May-12-25 05:55PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +9.23%
May-08-25 07:10AM	New Strong Sell Stocks for May 8th (Zacks)
May-01-25 07:00AM	Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 (PR Newswire) -15.41%
Apr-28-25 04:53AM	New Strong Sell Stocks for April 28th (Zacks)
Apr-24-25 06:25AM	New Strong Sell Stocks for April 24th (Zacks)
Apr-09-25 05:24AM	New Strong Sell Stocks for April 9th (Zacks) -14.80%
Mar-20-25 05:56PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update (PR Newswire) -10.95%
Mar-12-25 05:08PM	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
Mar-11-25 07:00AM	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit (PR Newswire) -6.50%
Dec-20-24 07:15AM	Armata Pharmas inhaled AP-PA02 shows positive results in Phase 2 study (TipRanks)
07:00AM	Loading…
Dec-19-24 07:00AM	Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire)
Nov-19-24 07:00AM	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting (PR Newswire) -11.61%
Nov-13-24 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update (PR Newswire)
Nov-12-24 07:00AM	Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia (PR Newswire) +22.22%
Oct-30-24 07:00AM	Armata Pharmaceuticals Announces Structural Biology Publication (PR Newswire)
Sep-12-24 12:00PM	Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-05-24 07:30AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-26-24 07:30AM	Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium (PR Newswire)
Aug-15-24 04:45PM	Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer (PR Newswire) -6.97%
Aug-13-24 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update (PR Newswire) +6.27% -10.70%
Jul-30-24 07:00AM	Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 (PR Newswire)
Jul-11-24 07:00AM	Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire) +11.94%
Jul-10-24 04:05PM	Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 (PR Newswire) +5.10%
May-07-24 04:01PM	Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update (PR Newswire) +13.94%
Mar-21-24 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update (PR Newswire)
04:01PM	Loading…
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire) -8.50%
Feb-21-24 07:00AM	Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit (PR Newswire)
Nov-14-23 04:00PM	Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update (PR Newswire) +8.94% -19.78%
Oct-30-23 08:00AM	Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference (PR Newswire) +10.19%
Oct-19-23 08:00AM	Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 (PR Newswire)
Sep-26-23 08:00AM	Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus (PR Newswire)
Sep-21-23 07:00AM	Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference (PR Newswire)
Aug-17-23 09:55AM	Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-14-23 07:00AM	Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update (PR Newswire)
Jul-11-23 08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
May-31-23 08:00AM	Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy (PR Newswire)
May-11-23 04:05PM	Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update (PR Newswire)
Mar-16-23 04:10PM	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update (PR Newswire) +5.42% +8.57%
Mar-06-23 06:00AM	Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis (PR Newswire) +10.87%
Jan-10-23 04:05PM	Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC (PR Newswire) +25.38%
Dec-22-22 08:00AM	Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection (PR Newswire) -6.99%
Dec-08-22 09:55AM	Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-28-22 09:35AM	After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP) (Zacks)
08:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (PR Newswire)
Nov-15-22 09:55AM	Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing (Zacks) -9.66%
Nov-09-22 04:15PM	Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update (PR Newswire) -8.23%
Aug-11-22 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update (PR Newswire)
Aug-01-22 08:00AM	Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections (PR Newswire)
May-23-22 08:00AM	Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus (PR Newswire)
May-12-22 04:17PM	Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update (PR Newswire) -5.00%
Mar-31-22 04:05PM	Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva (PR Newswire) -8.60%
Mar-22-22 10:00AM	Wall Street Analysts See a 52% Upside in Armata Pharmaceuticals, Inc. (ARMP): Can the Stock Really Move This High? (Zacks) +5.17%
Mar-17-22 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update (PR Newswire) +5.37% +17.74%
Mar-09-22 05:28PM	Armata Pharmaceuticals to move headquarters to Playa Vista (American City Business Journals)
Feb-22-22 08:00AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis (PR Newswire)
Feb-17-22 08:00AM	Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences (PR Newswire)
Feb-09-22 04:16PM	Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development (PR Newswire)
Jan-06-22 08:50AM	Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why (Zacks) +7.12%
Jan-05-22 08:00AM	Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs (PR Newswire) +6.12%
Nov-29-21 10:00AM	Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade (Zacks) -17.62%
Nov-18-21 08:00AM	Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs (PR Newswire)
Nov-17-21 12:00PM	What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock (Zacks) +8.07%
Nov-10-21 04:05PM	Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update (PR Newswire) -6.61%
Nov-04-21 03:01PM	Armata Pharmaceuticals, Inc. (ARMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress (PR Newswire)
Nov-02-21 08:00AM	Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility (PR Newswire)
Oct-28-21 06:41PM	Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals (PR Newswire) +6.67%
Sep-08-21 08:00AM	Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-12-21 04:05PM	Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update (PR Newswire)
Aug-05-21 03:00PM	Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know (Zacks)
Aug-02-21 07:30AM	Armata Pharmaceuticals Announces Chief Executive Officer Transition (PR Newswire)
Jul-07-21 07:30AM	Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (PR Newswire)
May-13-21 04:05PM	Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update (PR Newswire)
10:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire)
Mar-18-21 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update (PR Newswire)
Mar-17-21 04:01PM	Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva (PR Newswire)
Mar-16-21 11:01AM	Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference (PR Newswire)
Jan-27-21 07:01AM	Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs (PR Newswire)
Dec-09-20 07:30AM	Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors (PR Newswire)
Nov-16-20 11:10PM	Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts (Simply Wall St.) -13.97%
Nov-15-20 07:17AM	Earnings Beat: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts (Simply Wall St.)
Nov-12-20 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update (PR Newswire) +7.95% -7.36%
Oct-29-20 07:30AM	Armata Pharmaceuticals Issues Letter to Shareholders (PR Newswire) +7.00%
Oct-26-20 07:30AM	Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development (PR Newswire)
Oct-15-20 07:30AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections (PR Newswire) +8.86%
Sep-29-20 07:30AM	Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress (PR Newswire)
Sep-11-20 07:30AM	Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences (PR Newswire)
Aug-13-20 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update (PR Newswire)
Jun-30-20 06:05AM	Here's Why We're Watching Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Situation (Simply Wall St.)
Jun-17-20 07:30AM	Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections (PR Newswire) +10.33%
May-14-20 04:05PM	Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update (PR Newswire)
Apr-28-20 08:00AM	Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector (PR Newswire)
Mar-30-20 07:30AM	Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. (PR Newswire)
Mar-19-20 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update (PR Newswire) -6.46%
Mar-18-20 08:00AM	Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation (PR Newswire) +10.94%

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARMP

Armata Pharmaceuticals Inc

Upgrade your FINVIZ experience